🇺🇸 Lapelga in United States
57 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 57
Most-reported reactions
- Diarrhoea — 11 reports (19.3%)
- Dyspnoea — 6 reports (10.53%)
- Blood Creatinine Increased — 5 reports (8.77%)
- Blood Glucose Increased — 5 reports (8.77%)
- Contusion — 5 reports (8.77%)
- Fall — 5 reports (8.77%)
- Heart Rate Increased — 5 reports (8.77%)
- Peripheral Swelling — 5 reports (8.77%)
- Seasonal Allergy — 5 reports (8.77%)
- Thrombosis — 5 reports (8.77%)
Other Other approved in United States
Frequently asked questions
Is Lapelga approved in United States?
Lapelga does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Lapelga in United States?
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the originator. The local marketing authorisation holder may differ — check the official source linked above.